Shareholders approve Contract and Plan of Merger with Ebix A.

Common share were voted and only the merger through the Unique Meeting of Shareholders held on February 4, 2011. This vote exceeded the required threshold, which was approval by many vote of the exceptional shares. Of the shares voted, over 99 % voted and only the merger. Under the terms of the merger contract, at the closing of the merger, each share of common share of A.D.A.M. Will be converted into the right to get 0.3122 shares of common share of Ebix.The distribution of PLA2R in regular glomeruli suggests that it is located on podocytes, as are megalin in rat models of membranous nephropathy and neutral endopeptidase in sufferers with alloimmune neonatal membranous nephropathy. PLA2R colocalizes with IgG4 in immune deposits of kidney-biopsy specimens from individuals with idiopathic membranous nephropathy, and IgG eluted from such biopsy specimens is certainly reactive with PLA2R. Moreover, serial studies in a limited number of patients suggest that the presence of circulating anti-PLA2R antibodies corresponds to disease activity. Finally, the specificity of the reactivity of anti-PLA2R antibodies in sufferers with idiopathic membranous nephropathy, instead of secondary types of membranous nephropathy or other proteinuric diseases, shows that the antibodies are likely the cause, than a consequence rather, of podocyte proteinuria and injury.